Solubilization and characterization of a growth hormone secretagogue receptor from porcine anterior pituitary membranes.

Pomés A, Pong SS, Schaeffer JM

Biochemical and biophysical research communications1 Aug 1996Cited by 7 (Europe PMC)

PMID8780714DOI10.1006/bbrc.1996.1275PepBankPUB-08780714

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone7

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01LabNot a test of MK-677 (ibutamoren) aloneIn vitro (cell-free)Activity measurement
In lab tests, a porcine receptor complex labelled with MK-0677 had an apparent molecular mass of approximately 255 kDa.
In plain wordsIn lab tests, the MK-0677-labelled receptor complex had an apparent molecular mass of approximately 255 kDa.
Peptide
MK-677 (ibutamoren)
Outcome
Not applicableReceptor complex molecular mass
Study
pign: not reported in source
solubilized porcine anterior pituitary receptor
Outcome group
Receptor activity and mechanism · Pharmacology
Measurements
apparent molecular mass
≈ 255 kDa
receptor complex
Source sentences
Summary
We report the solubilization of the GH-secretagogue-receptor-ligand-G-protein complex (apparent molecular mass of approximately 255 kDa) from porcine anterior pituitary membranes using digitonin, after labelling the receptor with [35S]MK-0677.
In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MK-677 (ibutamoren).
Report a problemFND-0878071401
02LabNot a test of MK-677 (ibutamoren) aloneIn vitro (cell-free)Activity measurement
In lab tests, the solubilized porcine receptor showed high affinity for radiolabelled MK-0677.
In plain wordsIn lab tests, the solubilized porcine receptor showed high affinity for radiolabelled MK-0677.
Peptide
MK-677 (ibutamoren)
Outcome
Not applicableBinding affinity
Study
pign: not reported in source
solubilized porcine anterior pituitary receptor
Outcome group
Receptor activity and mechanism · Pharmacology
Measurements
KD
122.2 pM
solubilized receptor
Source sentences
Summary
The solubilized receptor showed high affinity (KD = 122.2 +/- 14.4 pM) and low capacity (Bmax = 3.8 +/- 0.9 fmol/mg protein).
1 context sentence(design, population, supporting numbers)
Summary · context
We report the solubilization of the GH-secretagogue-receptor-ligand-G-protein complex (apparent molecular mass of approximately 255 kDa) from porcine anterior pituitary membranes using digitonin, after labelling the receptor with [35S]MK-0677.
In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MK-677 (ibutamoren).
Report a problemFND-0878071402
03LabNot a test of MK-677 (ibutamoren) aloneIn vitro (cell-free)Activity measurement
In lab tests, the solubilized porcine receptor showed low binding capacity for radiolabelled MK-0677.
In plain wordsIn lab tests, the solubilized porcine receptor showed low binding capacity for radiolabelled MK-0677.
Peptide
MK-677 (ibutamoren)
Outcome
Not applicableBinding capacity
Study
pign: not reported in source
solubilized porcine anterior pituitary receptor
Outcome group
Receptor activity and mechanism · Pharmacology
Measurements
Bmax
3.8 fmol/mg protein
solubilized receptor
Source sentences
Summary
The solubilized receptor showed high affinity (KD = 122.2 +/- 14.4 pM) and low capacity (Bmax = 3.8 +/- 0.9 fmol/mg protein).
1 context sentence(design, population, supporting numbers)
Summary · context
We report the solubilization of the GH-secretagogue-receptor-ligand-G-protein complex (apparent molecular mass of approximately 255 kDa) from porcine anterior pituitary membranes using digitonin, after labelling the receptor with [35S]MK-0677.
In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MK-677 (ibutamoren).
Report a problemFND-0878071403
04LabNot a test of MK-677 (ibutamoren) aloneIn vitro (cell-free)Activity measurement
In lab tests, solubilized receptor affinity was similar to affinity in porcine pituitary membranes.
In plain wordsIn lab tests, solubilized receptor affinity was similar to affinity in porcine pituitary membranes.
Peptide
MK-677 (ibutamoren)
Outcome
No significant changeAffinity comparison with membranes
Study
pign: not reported in source
solubilized porcine anterior pituitary receptor
Comparator
isolated porcine anterior pituitary membranes
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
These values and the inhibition constants (Ki) for a series of GH secretagogues were similar to the values determined in membranes isolated from porcine anterior pituitary gland.
2 context sentences(design, population, supporting numbers)
Summary · context
The solubilized receptor showed high affinity (KD = 122.2 +/- 14.4 pM) and low capacity (Bmax = 3.8 +/- 0.9 fmol/mg protein).
Summary · context
We report the solubilization of the GH-secretagogue-receptor-ligand-G-protein complex (apparent molecular mass of approximately 255 kDa) from porcine anterior pituitary membranes using digitonin, after labelling the receptor with [35S]MK-0677.
In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MK-677 (ibutamoren).
Report a problemFND-0878071404
05LabNot a test of MK-677 (ibutamoren) aloneIn vitro (cell-free)Activity measurement
In lab tests, solubilized receptor capacity was similar to capacity in porcine pituitary membranes.
In plain wordsIn lab tests, solubilized receptor capacity was similar to capacity in porcine pituitary membranes.
Peptide
MK-677 (ibutamoren)
Outcome
No significant changeCapacity comparison with membranes
Study
pign: not reported in source
solubilized porcine anterior pituitary receptor
Comparator
isolated porcine anterior pituitary membranes
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
These values and the inhibition constants (Ki) for a series of GH secretagogues were similar to the values determined in membranes isolated from porcine anterior pituitary gland.
2 context sentences(design, population, supporting numbers)
Summary · context
The solubilized receptor showed high affinity (KD = 122.2 +/- 14.4 pM) and low capacity (Bmax = 3.8 +/- 0.9 fmol/mg protein).
Summary · context
We report the solubilization of the GH-secretagogue-receptor-ligand-G-protein complex (apparent molecular mass of approximately 255 kDa) from porcine anterior pituitary membranes using digitonin, after labelling the receptor with [35S]MK-0677.
In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MK-677 (ibutamoren).
Report a problemFND-0878071405
06LabNot a test of MK-677 (ibutamoren) aloneIn vitro (cell-free)Activity measurement
In lab tests, inhibition constants for a series of GH secretagogues were similar in solubilized receptors and pituitary membranes.
In plain wordsIn lab tests, inhibition constants for several GH secretagogues were similar in solubilized receptors and pituitary membranes.
Peptide
MK-677 (ibutamoren)
Outcome
No significant changeSecretagogue inhibition constants
Study
pign: not reported in source
solubilized porcine anterior pituitary receptor
Comparator
isolated porcine anterior pituitary membranes
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
These values and the inhibition constants (Ki) for a series of GH secretagogues were similar to the values determined in membranes isolated from porcine anterior pituitary gland.
1 context sentence(design, population, supporting numbers)
Summary · context
We report the solubilization of the GH-secretagogue-receptor-ligand-G-protein complex (apparent molecular mass of approximately 255 kDa) from porcine anterior pituitary membranes using digitonin, after labelling the receptor with [35S]MK-0677.
In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MK-677 (ibutamoren).
Report a problemFND-0878071406
07LabNot a test of GHRP-6 aloneIn vitro (cell-free)Activity measurement
In lab tests, inhibition constants for a series of GH secretagogues were similar in solubilized receptors and pituitary membranes.
In plain wordsIn lab tests, inhibition constants for several GH secretagogues were similar in solubilized receptors and pituitary membranes.
Peptide
GHRP-6
Outcome
No significant changeSecretagogue inhibition constants
Study
pign: not reported in source
solubilized porcine anterior pituitary receptor
Comparator
isolated porcine anterior pituitary membranes
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
These values and the inhibition constants (Ki) for a series of GH secretagogues were similar to the values determined in membranes isolated from porcine anterior pituitary gland.
1 context sentence(design, population, supporting numbers)
Summary · context
We report the solubilization of the GH-secretagogue-receptor-ligand-G-protein complex (apparent molecular mass of approximately 255 kDa) from porcine anterior pituitary membranes using digitonin, after labelling the receptor with [35S]MK-0677.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-0878071407

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 2
14 Oct 2026, 01:46 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.